VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC lessened its stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) by 24.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 152,973 shares of the company’s stock after selling 50,000 shares during the quarter. Parkman Healthcare Partners LLC owned about 1.04% of VYNE Therapeutics worth $512,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Acorn Capital Advisors LLC acquired a new stake in shares of VYNE Therapeutics in the fourth quarter valued at approximately $1,531,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at $823,000. Schonfeld Strategic Advisors LLC lifted its stake in shares of VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after purchasing an additional 8,058 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at $516,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at $124,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Trading Up 4.8%

VYNE opened at $1.31 on Wednesday. The stock’s 50-day moving average price is $1.64 and its 200 day moving average price is $2.39. VYNE Therapeutics Inc. has a 12-month low of $1.18 and a 12-month high of $4.30. The firm has a market cap of $19.93 million, a price-to-earnings ratio of -1.52 and a beta of 1.76.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.05 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. On average, research analysts forecast that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating on the stock in a research note on Friday, April 25th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.